By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
Drugs in Development Information for Sotrastaurin
Email this page to a colleague
What is the drug development status for Sotrastaurin?
Sotrastaurin is an investigational drug.
There have been 6 clinical trials for Sotrastaurin.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.
The most common disease conditions in clinical trials are Uveal Neoplasms, Melanoma, and Lymphoma, Mantle-Cell. The leading clinical trial sponsors are Novartis Pharmaceuticals, Array BioPharma, and James Blachly.
Summary for Sotrastaurin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 439 |
| WIPO Patent Applications | 318 |
| Japanese Patent Applications | 151 |
| Clinical Trial Progress | Phase 2 (2009-12-01) |
| Vendors | 49 |
Recent Clinical Trials for Sotrastaurin
| Title | Sponsor | Phase |
|---|---|---|
| Trial of AEB071 in Combination With BYL719 in Patients With Melanoma | Richard D. Carvajal | Phase 1 |
| A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | Array BioPharma | Phase 1/Phase 2 |
| Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients | Novartis Pharmaceuticals | Phase 2 |
Clinical Trial Summary for Sotrastaurin
Top disease conditions for Sotrastaurin
Top clinical trial sponsors for Sotrastaurin
US Patents for Sotrastaurin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
